 |
| CrossRef Text and Data Mining |
| Result of CrossRef Text and Data Mining Search is the related articles with entitled article. If you click link1 or link2 you will be able to reach the full text site of selected articles; however, some links do not show the full text immediately at now. If you click CrossRef Text and Data Mining Download icon, you will be able to get whole list of articles from literature included in CrossRef Text and Data Mining. |
| Clinical Implication of Tolvaptan in Patients with Autosomal Dominant Polycystic Kidney Disease |
| Semin Cho, Jin Hyuk Paek, Woo Yeong Park, Kyubok Jin, Dong Ki Kim, Seungyeup Han, Yaerim Kim |
|
Keimyung Med J. 2022;41(1):24-31. Published online June 13, 2022 DOI: https://doi.org/10.46308/kmj.2022.00059 |
|
Will introduction of tolvaptan change clinical practice in autosomal dominant polycystic kidney disease? Kidney International. 2015;88(1):14-16  Clinical Implication of Tolvaptan in Patients with Autosomal Dominant Polycystic Kidney Disease Keimyung Medical Journal. 2022;41(1):24-31 Commentary on: Tolvaptan in Patients With Autosomal-Dominant Polycystic Kidney Disease Urology. 2013;81(4):705-706 The effect of tolvaptan on kidney function in patients with autosomal dominant polycystic kidney disease Clinical and Experimental Nephrology. 2015;20(1):147-148 Safety Profile of Tolvaptan in the Treatment of Autosomal Dominant Polycystic Kidney Disease Therapeutics and Clinical Risk Management. 2021;Volume 17:649-656 In Reply to “The effect of tolvaptan on kidney function in patients with autosomal dominant polycystic kidney disease” Clinical and Experimental Nephrology. 2015;20(1):149-150 274 Impact of Tolvaptan on Costs Associated with Renal Pain and Chronic Kidney Disease Among Patients with Autosomal Dominant Polycystic Kidney Disease American Journal of Kidney Diseases. 2018;71(4):584 Tolvaptan: A Review in Autosomal Dominant Polycystic Kidney Disease Drugs. 2019;79(3):303-313 233 Benefit of Tolvaptan on Time to End-stage Renal Disease (ESRD) for Patients with Rapidly Progressing Autosomal Dominant Polycystic Kidney Disease (ADPKD): A Disease Progression Model American Journal of Kidney Diseases. 2020;75(4):603 MO027: Clinical efficacy of treatment with tolvaptan in patients with autosomal dominant polycystic kidney disease Nephrology Dialysis Transplantation. 2022;37(Supplement_3): |
